J Drugs Dermatol. 2009 Feb; 8(2): 120-3Elewski BEA survey of people with rosacea was conducted in 2006 to gain insight into experiences with rosacea therapies and relationships with health care providers. The survey was completed by 2946 participants, of whom 2847 had been diagnosed with rosacea. Participants ranged in age from 20 to 81 years (mean age 50 years). Among those diagnosed with rosacea, 80% agreed that medication prevented their rosacea from worsening. Most respondents currently using prescription medication (82%) did not plan to discontinue its use. Among current users of medication, 46% had switched from a prior agent, usually due to the lack of improvement. Among respondents who previously switched therapies, 84% reported using some formulation of topical metronidazole. Of those respondents who discussed rosacea with their physician, 83% agreed that their physician influences their use of medication; 61% viewed their physician-in most cases a dermatologist-as a partner in managing their rosacea.
Rosacea is a common skin condition but the treatments currently available are not satisfactory. OBJECTIVES: To assess the efficacy of intense pulsed light (IPL) for treatment of stage I rosacea (flushing, erythema and telangiectasia). METHODS: Thirty-four patients were treated, 25 women and nine men, mean age 47 years. The treatment employed was IPL 515-1200 nm, with a 560 nm cut-off filter. The fluence range was 24-32 J cm(-2). Four treatments were administered on the face at 3-week intervals. Erythema values were measured at baseline and at the end of the treatment period on the cheeks and chin. Digital photographs were assessed by a consultant dermatologist on a 10-point visual analogue scale (VAS). Patients' assessments were also made using a 10-point VAS. Outcome measures were repeated 6 months after treatment. RESULTS: After four treatments the mean reduction of the erythema values was 39% on the cheeks (P The severity of rosacea was reduced on average by 3.5 points on the 10...